GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Eric Stier sold 1,703 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $6.25, for a total value of $10,643.75. Following the completion of the transaction, the senior vice president now owns 133,892 shares in the company, valued at $836,825. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of GNMK stock traded up $0.03 on Thursday, reaching $6.31. The stock had a trading volume of 1,852 shares, compared to its average volume of 357,277. The stock has a market cap of $366.46 million, a P/E ratio of -6.96 and a beta of 1.27. The company has a debt-to-equity ratio of 3.69, a quick ratio of 2.83 and a current ratio of 3.39. The company has a 50 day simple moving average of $6.37 and a 200 day simple moving average of $6.82. GenMark Diagnostics, Inc has a 1 year low of $3.58 and a 1 year high of $8.81.
GenMark Diagnostics (NASDAQ:GNMK) last released its earnings results on Monday, August 5th. The medical equipment provider reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.02). The company had revenue of $18.37 million for the quarter, compared to analysts’ expectations of $17.92 million. GenMark Diagnostics had a negative net margin of 63.86% and a negative return on equity of 167.54%. On average, equities research analysts anticipate that GenMark Diagnostics, Inc will post -0.8 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GNMK. Bank of Montreal Can lifted its position in GenMark Diagnostics by 145.4% during the second quarter. Bank of Montreal Can now owns 7,687 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 4,554 shares in the last quarter. Legal & General Group Plc lifted its position in GenMark Diagnostics by 48.6% during the fourth quarter. Legal & General Group Plc now owns 11,308 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 3,700 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in GenMark Diagnostics by 56,694.7% during the first quarter. BNP Paribas Arbitrage SA now owns 10,791 shares of the medical equipment provider’s stock valued at $77,000 after purchasing an additional 10,772 shares in the last quarter. SG Americas Securities LLC purchased a new position in GenMark Diagnostics during the second quarter valued at $79,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in GenMark Diagnostics by 365.1% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 18,530 shares of the medical equipment provider’s stock valued at $90,000 after purchasing an additional 14,546 shares in the last quarter. Institutional investors own 89.91% of the company’s stock.
About GenMark Diagnostics
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Recommended Story: Holder of Record
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.